As of January 22, 2025, CG Oncology (CGON) has a market cap of $2.25 billion USD. According to our data, CG Oncology is ranked No.3947 in global market value.
Year | Market Cap | %Change |
---|---|---|
Jan 22, 2025 | $2.25 B |
3.28%
|
Dec 31, 2024 | $2.18 B |
100%
|
Name | Market Cap | Market cap difference | Regions |
---|---|---|---|
Bristol-Myers Squibb
BMY
|
$115.86 B |
0.003 M
|
USA
|
Merck
MRK
|
$242.59 B |
0.007 M
|
USA
|
Pfizer
PFE
|
$148.34 B |
-0.006 M
|
USA
|
Johnson & Johnson
JNJ
|
$347.78 B |
-0.005 M
|
USA
|
AstraZeneca
AZN
|
$211.43 B |
0.005 M
|
UK
|
Novartis
NVS
|
$197.43 B |
0.007 M
|
Switzerland
|
GlaxoSmithKline
GSK
|
$68.38 B |
0.002 M
|
UK
|
Amgen
AMGN
|
$147.53 B |
0.002 M
|
USA
|
Gilead Sciences
GILD
|
$116.07 B |
0.004 M
|
USA
|
Eli Lilly
LLY
|
$676.92 B |
0.020 M
|
USA
|
Sanofi
SNY
|
$128.55 B |
0.003 M
|
France
|
AbbVie
ABBV
|
$300.53 B |
0.002 M
|
USA
|
Regeneron Pharmaceuticals
REGN
|
$75.23 B |
1.245 B
|
USA
|
Biogen
BIIB
|
$20.80 B |
-0.001 M
|
USA
|
Market Cap | = | CGON Stock Price | * | CGON Shares Outstanding |
= | $29.62 | * | 76.13 M | |
= | $2.25 B |